Whitehawk Q2 2026 earnings: Cash runway extends into the second half of 2028

Whitehawk Therapeutics (Nasdaq: WHWK) reported no revenue for Q2 2026, unchanged from a year earlier, while diluted net loss per share narrowed to $0.20 from $0.76. The smaller loss largely reflected the absence of a prior-year $38.0 million upfront license fee, while an $87.5 million private placement helped lift cash and short-term investments to $190.0 million.

Core financial results

As a clinical-stage company without quarterly product revenue, Whitehawk’s results were driven primarily by research and development spending, general and administrative expenses, and interest income. The year-over-year comparison was materially affected by the upfront licensing payment included in Q2 2025.

Dollar figures below are in millions except per-share data.

Interest income of $1.5 million partly offset operating expenses, compared with $2.0 million in the prior-year quarter.

Clinical pipeline and operating milestones

Whitehawk continued enrolling patients in two Phase 1 studies during the quarter:

• HWK-007 is being evaluated in non-squamous, EGFR wild-type non-small cell lung cancer, platinum-resistant ovarian cancer, and endometrial cancer.
• HWK-016 is being studied in advanced ovarian and endometrial cancers.

Initial results from both programs are expected in the first half of 2027. The company also plans to initiate a Phase 1 study of HWK-206 in small-cell lung cancer and neuroendocrine tumors during Q3 2026.

Beyond its three clinical assets, Whitehawk entered an option agreement with Hangzhou DAC covering CPT113 technology for as many as five additional ADC programs. It also began a collaboration with Biocytogen that provides access to up to five bispecific antibodies for potential bispecific ADC development. Management anticipates submitting IND applications for multiple new ADC programs over the next 12 to 24 months.

Profitability and balance sheet

The decline in reported R&D expense should not be interpreted as an equivalent reduction in underlying clinical activity. Q2 2025 R&D expense included a $38.0 million upfront license payment to WuXi Biologics; excluding that payment, prior-year R&D expense was approximately $10.8 million, compared with $12.9 million this quarter.

Cash, cash equivalents and short-term investments totaled $190.0 million at June 30, 2026, up from $145.7 million at December 31, 2025. The increase followed the company’s $87.5 million private placement in May. Based on current operating plans, Whitehawk expects these resources to fund operations into the second half of 2028.

Recent insider transactions

The supplied insider-trading summary reports 3,334,312 shares categorized as purchases across 12 transactions during the past six months, versus 705,358 shares sold across nine transactions. That produced reported net purchases of 2,628,954 shares, although the newest records include stock awards and therefore should not be viewed entirely as open-market buying.

The 10 latest reported transactions consisted of six stock awards on May 14 and four sales during April.

These transactions describe changes in insider ownership but do not, on their own, establish management’s view of the company’s prospects.

Risks investors need to watch

• Clinical execution: Delays in enrollment, study initiation, or completion could affect the planned Q3 2026 start for HWK-206 and the expected first-half 2027 data from HWK-007 and HWK-016.
• Early-stage development risk: Whitehawk’s programs remain in Phase 1 development and still need to demonstrate acceptable safety and efficacy.
• Ongoing losses without product revenue: The company generated no quarterly revenue and recorded a $16.6 million net loss, leaving operations dependent on available capital.
• Runway assumptions: The projection that cash will fund operations into the second half of 2028 is based on current plans and could change with clinical costs, development timelines, or pipeline expansion.

Summary

Whitehawk’s narrower Q2 loss primarily reflected the absence of a large prior-year licensing payment rather than revenue generation or a comparable reduction in development activity. The financing completed during the quarter extended the expected cash runway, giving the company additional time to advance three Phase 1 ADC programs. The next important operating checkpoints are the planned HWK-206 trial launch and initial HWK-007 and HWK-016 results.